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CASE PRESENTATION
A 55-year-old male with end-stage renal disease (ESRD)
secondary to diabetic nephropathy on hemodialysis for
2 years via a tunneled catheter line was admitted to the
Brigham & Women’s Hospital with chest pain. The chest
pain was localized to the midline, radiated to the left arm,
and was present at rest with no diaphoresis. His cardiac
enzymes were elevated (troponin-I of 11.46 ng/ml
and creatinine kinase-MB of 30.7 ng/ml) and his
electrocardiogram (EKG) showed nonspecific ST–T wave
changes that were unchanged from previous EKG 6
months earlier. He had a history of coronary artery disease
(CAD) status post coronary artery bypass graft (CABG)
10 months earlier, type 1 diabetes mellitus since the
age of 6 years, and peripheral neuropathy, blindness
secondary to proliferative retinopathy, gastroparesis,
neurogenic bladder, peripheral vascular disease
(above-knee amputation of right limb), hypertension,
and hypercholesterolemia. He had a failed living-related
renal transplant because of recurrent diabetic
nephropathy and chronic allograft nephropathy after
15 years. He had no history of stroke. His medications
included aspirin, metoprolol, simvastatin, gemfibrozil,
insulin, calcium acetate, sevelamer, epoeitin alfa,
methadone, and hydromorphone hydrochloride. There
was no significant family history of cardiovascular or renal
disease. On physical examination, he was alert and
afebrile, with a blood pressure of 135/60 mmHg, heart rate
of 70 beats per minute, respiratory rate of 14 breaths
per minute, with an oxygen saturation of 100% on room
air and jugular venous pressure of 7 cm. His tunneled
catheter site on the right side of the neck was clean,
with no tenderness or erythema. Cardiac examination
revealed distant heart sounds with no murmurs.
The rest of the examination was unremarkable.
CLINICAL DIAGNOSIS
A clinical diagnosis of acute coronary syndrome (ACS)
(a non-ST-elevation myocardial infarction (MI)) was made.
CLINICAL FOLLOW-UP
The patient was admitted with a provisional diagnosis
of non-ST-elevation MI. He was managed medically
with aspirin, beta-blockers, statin, and heparin. However,
he did not receive clopidogrel, thrombolytics, or emergent
catheterization because of substantial comorbidities and
because it was unclear if any further intervention would
be beneficial. He remained chest pain-free during the
hospital stay. Subsequently, he underwent an echocardiogram
4 days after admission that showed an ejection fraction
of 55–60% with no wall-motion abnormalities and a
moderate enlargement of the left atrium. These findings
were similar to an echocardiogram performed 6 months
earlier. Five days after admission, a cardiac catheterization
was performed (Figure 1), which revealed a left dominant
system with a patent left internal mammary artery to left
anterior descending graft (Figure 1c) and saphaneous vein
graft to distal obtuse marginal 1 graft (Figure 1d).
Progression of disease in his native coronary arteries was
significant with a new total occlusion of the right coronary
artery, progression to total occlusion in previously noted
obtuse marginal and left anterior descending artery lesions,
and a new, ostial left circumflex lesions. No interventions
were performed.
With therapy, his troponins and creatinine kinase-MB
gradually trended down (Figure 2) and he was discharged 8
days after admission. There was no change in his medications
as compared to before his admission.
DISCUSSION
This patient with ESRD on hemodialysis presented with
ACS and subsequently underwent cardiac catheterization
5 days after presentation. This patient’s presentation raises
several important issues with regard to the secondary
prevention and acute management of ACS in ESRD patients:
first, the increasing burden of CAD in dialysis patients and
the challenges associated in its accurate diagnosis; second, the
frequent underutilization of standard management/preven-
tive measures for CAD in ESRD patients; and lastly, the
appropriate management of ACS and relevance of consensus
guidelines aimed at the general population for the treatment
of ACS in patients with ESRD.
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Epidemiology/burden of CAD in ESRD patients
In 2004, the 1-year mortality for patients with ESRD was
22.54%.1 However, the survival after the occurrence of an MI
decreases markedly. During the year after MI, mortality rises
to nearly 60%,2 and approaches 75% at 2 years.2 Conversely,
less than 10% of dialysis-dependant patients survive 5 years
post MI.2
Myocardial infarction and cardiovascular disease are
frequent complications in patients on chronic dialysis.
Cardiovascular disease is the leading cause of death among
dialysis patients, accounting for approximately 40% of all
deaths;3 Of this 40%, approximately 17% is attributable to
ACS.1 Among patients initiating dialysis, the incidence
of ACS and congestive heart failure during a follow up of
2.2 years were 10.2 and 13.6%, respectively.4 From large
databases of patients with ESRD, the prevalence of CAD
and congestive heart failure are 36 and 39%, respectively.5
This high rate of cardiovascular complications is at
least partially due to extensive cardiovascular disease in
patients both when they initiate dialysis and subsequently.6
Foley et al.7 and others have documented a prevalence of
left ventricular hypertrophy of 74% in this population—
almost two-fold greater than the 38% prevalence found in
a study of pre-ESRD patients. Conversely, in a series of
consecutive incident dialysis patients who underwent
cardiac catheterization, more than 60% of patients had
significant CAD (defined as more than 75% narrowing of
a major coronary artery), with an average of 3.3 lesions
per patient.8
In summary, patients maintained on chronic dialysis
have a high burden of atherosclerotic coronary disease that
is associated with an excessively high risk of developing MI
and congestive heart failure. Most importantly, it must be
appreciated that the risk of cardiovascular death in the
dialysis population as a whole is several times higher than
other high-risk populations such as patients without renal
disease admitted with an MI complicated by congestive heart
failure.5,9 Thus, it may be reasonable to consider dialysis-
dependant ESRD as a coronary heart disease equivalent
and to consider aggressive use of anti-ischemic and anti-
atherosclerotic therapies in all patients on dialysis.
Whether the dialysis procedure itself imposes further
ischemia is controversial. Some have suggested that hypoxia
during dialysis, rapid fluid and/or solute shifts, and hemo-
dynamic changes may contribute. However, trial data to date
has been very limited.
Challenges in accurate diagnosis of CAD in ESRD patients
The management of CAD in patients with chronic kidney
disease (CKD) is more challenging than in patients with
normal kidney function. This is partly because of the limited
predictive value of the traditional triad of symptoms, EKG
findings, and cardiac biomarkers in diagnosing ACS in
dialysis patients.
Although chest pain is considered to be the cardinal
manifestation of coronary ischemia, patients with both
predialysis CKD10 and ESRD11 present with chest pain as
their chief complaint much less frequently than patients with
normal renal function. In fact, fewer than 50% of dialysis
patients with MI present with chest pain, which likely
explains why MI is infrequently suspected on admission.11
Reasons for the different presentations of ischemia are not
well understood but may be related to associated diabetic or
uremic neuropathy. Diagnosis of ischemia is further compli-
cated by the fact that other symptoms of ischemia, such as
dyspnea on exertion, fatigue, and hypotension, are common
in dialysis patients and may be attributed to dialysis-related
Figure 1 | Images of cardiac catheterization of the index
patient. Cardiac catheterization showing grossly normal (a) left
coronary and (b) right coronary and a (c) patent left internal
mammary artery to left anterior descending graft and
(d) saphaneous vein graft to obtuse marginal 1 graft.
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Figure 2 | Trends in serum troponin-I and creatinine
kinase-MB during hospital stay.
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factors such anemia, volume overload, acidosis, non-
compliance with fluid intake or dialysis or to ultra-filtration
during dialysis.
An additional problem in diagnosing ACS is that the
primary tests used to diagnose ACS perform poorly in
patients with dialysis-dependant CKD. Cardiac enzyme (CK,
creatinine kinase-MB and troponin) elevations have been
observed on routine testing in dialysis patients without
clinical evidence of acute ischemia.12 In a study by Ooi et al.,
approximately 29% of patients without overt acute coronary
disease had an elevated level of troponin T.13 Furthermore,
only about 11% of patients had concentrations less than
0.01 mg/l (that is, as typically observed in a nonuremic
population). Several other studies have also reported false-
positive elevations in troponin T levels in ESRD patients
without ACS.14,15 Furthermore, one-, two-, and three-year
cumulative mortality rates were increased for patients who
had elevated troponin T levels as compared with those who
had normal/undetectable levels.16 The 2-year mortality rate
for those with cTnT o0.01 (n¼ 132) was 8.4 versus 26% for
those with minor increases (cTnTX0.01 but o0.04 mg/l;
n¼ 214); 39% with moderate increases (cTnTX0.04 but
o0.1 mg/l; n¼ 239); and 47% with larger increases (cTnT
X0.1 mg/l; n¼ 148).
The EKG may be difficult to interpret due to the frequent
presence of left ventricular hypertrophy and pathologic Q
waves at baseline as well the presence of ST depression in
many patients without clinically evident myocardial ischemia
during routine hemodialysis sessions.17 Furthermore, ST
elevation, the most striking electrical sign of ischemia in
patients with an MI, is 50% less frequent in those on dialysis
versus the nondialysis population. Difficulty in interpreting
the EKG may also compromise the utility of exercise stress
testing as a tool for the diagnosis of coronary ischemia. The
presence of baseline EKG abnormalities along with an
inability to reach target heart rate in exercise electrocardio-
graphic testing lowers the sensitivity and specificity of these
modalities in CKD patients.18 Although there is data that
suggest a lower accuracy for CAD detection in dialysis
patients using stress nuclear or echocardiographic imaging
techniques, compared with the general population,19 echo-
cardiographic and nuclear imaging-based stress testing do
appear to perform relatively well as prognostic tools and have
at least moderate sensitivity for the detection of advanced
obstructive CAD in dialysis patients.18,20 Combined dipyri-
damole and exercise thallium imaging may provide increased
accuracy in hemodialysis patients. The sensitivity, specificity,
positive and negative predictive values, and overall accuracy
of thallium imaging were 92, 89, 71, 98, and 90%,
respectively.20 Currently, the ‘Kidney Disease Outcomes
Quality Initiative’ guidelines suggest that dobutamine
echocardiography is preferred to vasodilator-induced stress
nuclear scintigraphy in diagnosing obstructive CAD in the
dialysis population,21 although this data should be reeval-
uated periodically as nuclear and echocardiographic techni-
ques continue to be refined.
With advances in technology, newer modalities may
ultimately emerge as alternative tools for the detection of
CAD in dialysis patients. Contrast enhanced cardiac magnetic
resonance imaging allows for very sensitive detection of focal
myocardial necrosis or fibrosis,22 and both cardiac magnetic
resonance imaging and computed tomography angiography
may also allow for noninvasive detection of obstructive
coronary disease. However, neither computed tomography
angiography nor cardiac magnetic resonance imaging have
emerged as standard clinical tools. Indeed, at the present
time, the risk of nephrogenic fibrosing dermopathy23 is a
significant limitation to the use of cardiac magnetic
resonance imaging in CKD patients.
This cluster of atypical symptoms and the lack of data
to guide the ideal diagnostic approach in dialysis patients
make the detection of CAD very challenging in this patient
population. Clinical acumen and the maintenance of a high-
index of suspicion for the presence of coronary disease
remain critical tools for clinicians taking care of patients with
ESRD.
Inadequate secondary prevention of CAD in ESRD patients
There is growing concern that CKD patients receive
inadequate preventive care for CAD. Although the guidelines
promulgated by Kidney Disease Outcomes Quality Initia-
tive21 and ‘American Heart Association’/‘American College
of Cardiology’24 recommend the use of aspirin, statins,
beta-blockers, angiotensin-converting enzyme inhibitors, and
early coronary interventions in patients with ACS, patients
with CKD are less likely than non-CKD patients to receive
these therapies.9,25–27 Winkelmayer et al.28 studied the use
of angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers, beta-blockers, and statins in dialysis
patients with MI and reported that only 49, 45, and 29%
of patients received these agents within the first 90 days
following discharge with an MI. Similar results were reported
by Berger et al.25 with the use of aspirin, beta-blockers, and
angiotensin-converting enzyme inhibitors. These authors also
suggested that secondary preventive measures were associated
with lower 30-day mortality in this patient population
(50, 40, and 48% relative reduction and 20.7, 13.6, and 16.1%
absolute reductions in mortality, respectively). The use of
glycoprotein IIb/IIIa receptor antagonists was also lower in
patients as the renal function declined, despite a mortality-
protective benefit after adjustment for degree of renal
dysfunction.29 However, as the renal function deteriorated,
the risk of bleeding increased. CKD patients also undergo
coronary angiography less frequently as compared with non-
CKD patients despite the fact that angiography appears to be
associated with lower mortality in CKD patients.26,30,31
Similarly, elderly patients with Stage 3 or higher CKD
undergo coronary angiography after MI less frequently than
patients with mild or no CKD.32
Chertow et al.26 highlighted the underutilization of
coronary angiography by demonstrating that only 25.2%
of CKD patients underwent angiography as compared with
560 Kidney International (2009) 75, 558–562
t h e r e n a l c o n s u l t SP Surana et al.: ACS in ESRD patients
46.8% of non-CKD patients and that these differences
persisted even among well-suited candidates for angiography.
Furthermore, 1-year mortality was 30.2% in CKD patients
who underwent angiography as compared with 60.2% in
those who did not.26 Although randomized data are lacking,
it appears that the use of coronary angiography is associated
with a significant reduction in the risk of death in patients
with advanced CKD26 and that this intervention should be
strongly considered in patients with ACS regardless of renal
function.
Collectively, these studies are limited by the presence of
selection bias, wherein the subjects who received cardiopro-
tective medications and angiography may be a healthier
cohort with fewer comorbid conditions compared with the
subjects who did not receive such therapy. This may partly
explain the reduced survival in the latter group of patients.
Furthermore, sample sizes are generally small, raising
concerns about generalizibility.
Recommendations
Given the high-risk burden of coronary disease in the dialysis
population, it is reasonable to perform screening for
cardiovascular disease when initiating chronic dialysis
therapy. Kidney Disease Outcomes Quality Initiative guide-
lines suggest that the work-up should include at least a
baseline EKG and an echocardiogram.21 All dialysis patients
with CAD who are not allergic to aspirin should receive
aspirin, and the use of beta-blockers, statins, and angioten-
sin-converting enzyme inhibitors should be considered in
patients without contraindications.21
When patients present with signs or symptoms suggestive
of coronary ischemia, maintenance of a high index of
suspicion is important. Interpretation of diagnostic tests
should be made in the context of the high prevalence of CAD
and ACS in the dialysis population, recognizing that the post-
test probability of CAD may remain high despite negative
(noninvasive) diagnostic tests.33 Once ACS is diagnosed,
guidelines recommend that the treatment of ACS in dialysis
patients should be similar to that of the non-dialysis patient
population (summarized in Table 1). Patients should receive
aspirin, beta-blockers, statins, thrombolytic therapy, percu-
taneous coronary intervention, and CABG according to the
usual indications.21 Unfractionated heparin and low mole-
cular weight heparin have been used in patients with unstable
angina and ACS. The use of low molecular weight heparin is
controversial from the perspective of dosage adjustment, as
its clearance is affected by kidney function and because of the
difficulty of monitoring factor Xa levels in the outpatient
setting. Collet et al.34 reported significantly lower 30-day
mortality with the use of low molecular weight heparin
compared with unfractionated heparin (4.2 versus 6.2%,
P¼ 0.0001). Glycoprotein IIb/IIIa receptor antagonists
should also be considered as an adjunctive therapy, with
abciximab and tirofiban as preferred agents (no dosing
changes for abciximab and dialysis-specific dosing recom-
mendations are available for tirofiban).
Furthermore, MI patients with ST-segment elevation
should receive acute reperfusion therapy if emergent
percutaneous coronary intervention is unavailable.21 Percu-
taneous coronary intervention/CABG are appropriate revas-
cularization techniques for symptomatic ischemia, and
CABG should be considered in those with three-vessel and/
or left main disease.21 Clopidogrel should be prescribed for
all patients with coronary stents and considered in other
patients with stable CAD or established atherosclerotic
cardiovascular disease.21
It must be noted that randomized data supporting these
recommendations are not yet available in the dialysis
population.35 In fact, prospective trials of standardized
cardiovascular therapies have generally suggested lower
efficacy in the dialysis population than the general popula-
tion.36,37 Further studies to determine how to optimize
treatment of CAD in the dialysis population are badly
needed, but the preceding recommendations represent a
reasonable approach based on a synthesis of currently
available evidence.
CONCLUSION
The prognosis of patients with ESRD is poor, and this stems
in part from a high frequency of ACS and a high mortality
from ACS among dialysis patients. This high risk is likely
multifactorial, representing an interplay of unique patho-
physiologic factors. Underdiagnosis and/or inadequate treat-
ment of underlying CAD in these difficult patients, the wide
spectrum of ‘atypical clinical presentations’, performance of
diagnostic tests, and underutilization of standard therapies
are areas that merit further study in this patient population.
Given the high risk of cardiovascular death in this
population, we believe aggressive workup and treatment of
ischemia have the potential to save lives and are warranted,
while we await the availability of randomized data in the
dialysis population.
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